Exelixis Reports Final STELLAR‑303 Analysis; Zanzalintinib In Combination With Tecentriq Showed Non‑Significant OS Trend Favoring Combo In Non‑Liver Metastases mCRC

Loading news article.

Exelixis Reports Final STELLAR‑303 Analysis; Zanzalintinib In Combination With Tecentriq Showed Non‑Significant OS Trend Favoring Combo In Non‑Liver Metastases mCRC | WAPE

Exelixis Reports Final STELLAR‑303 Analysis; Zanzalintinib In Combination With Tecentriq Showed Non‑Significant OS Trend Favoring Combo In Non‑Liver Metastases mCRC

Article summary

Related companies

Comments —